Biblio
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2024.
Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024.
. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. Bone Marrow Transplant. 2024.
Management of Patients undergoing CAR-T cell therapy in Germany. Oncol Res Treat. 2024.
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant. 2024.
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica. 2023.
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marr. Bone Marrow Transplant. 2023.
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023;16(1):96.
.
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.